-
IP addresses are NOT logged in this forum so there's no point asking. Please note that this forum is full of homophobes, racists, lunatics, schizophrenics & absolute nut jobs with a smattering of geniuses, Chinese chauvinists, Moderate Muslims and last but not least a couple of "know-it-alls" constantly sprouting their dubious wisdom. If you believe that content generated by unsavory characters might cause you offense PLEASE LEAVE NOW! Sammyboy Admin and Staff are not responsible for your hurt feelings should you choose to read any of the content here. The OTHER forum is HERE so please stop asking.
Taiho Pharmaceutical Launches HSP90 Inhibitor Jeselhy Tablets 40 mg (Pimitespib)
- Thread starter ginfreely
- Start date
Based on the results of a Phase III trial (CHAPTER-GIST-301 trial) comparing the efficacy and safety of Jeselhy versus placebo in patients with previously treated gastrointestinal stromal tumor (GIST),*1Jeselhy received manufacturing and marketing approval in June for the indication of GIST that has progressed after chemotherapy.
Taiho Pharmaceutical will promote the proper use of Jeselhy tablets for treating GIST, for which there are major unmet medical needs, to ensure that it can contribute to the needs of patients with GIST and healthcare professionals.
Hey you Cantonese dog son of chicken so bloody thick skinned how many times must I tell you not to come into my cancer thread to take benefits and then so shameless evil ingrate smear and insult me hokkien virgin with annulled marriage as slut. Pui!
About CHAPTER-GIST-301 Trial
This was a randomized, double-blind, Phase III clinical trial comparing Jeselhy with placebo in patients with GIST judged to be refractory to or intolerant of standard treatments. The primary endpoint in this trial was progression-free survival (PFS) and the secondary endpoint measures included overall survival (OS) and safety, as well as quality of life (QOL). Eighty-six patients with GIST who were at least 20 years old, and had previously been treated with imatinib, sunitinib, and regorafenib, were enrolled between October 2018 and April 2020 from six Japanese medical institutions specialized in GIST.
For more information on the CHAPTER-GIST-301 trial, please visit (JapicCTI-184094)
https://www.clinicaltrials.jp/cti-user/trial/Search.jsp
CHAPTER-GIST-301 trial: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL OF TAS-116 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR, CHAPTER; The molecular CHAperone heat shock protein 90 (HSP90) inhibitor, PimiTEspibib
For more information on the CHAPTER-GIST-301 trial, please visit (JapicCTI-184094)
https://www.clinicaltrials.jp/cti-user/trial/Search.jsp
CHAPTER-GIST-301 trial: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL OF TAS-116 IN PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR, CHAPTER; The molecular CHAperone heat shock protein 90 (HSP90) inhibitor, PimiTEspibib
About GIST (Gastrointestinal Stromal Tumor)
GIST develops in the walls of the gastrointestinal tract (frequently in the stomach and small intestine and rarely in the large intestine and esophagus) and is a type of malignant tumor (sarcoma) that causes metastasis and relapses. It has different characteristics than gastric and colorectal cancers that develop from mucous membrane.*2 The incidence in Japan is estimated to be roughly 1,500 to 2,500 patients per year (calculated based on the annual incidence rate reported in different countries),*3 making it a rare cancer. In many cases of GIST, there are mutations in the KIT and PDGFRA genes, which are involved in the growth and survival of cancer. All GIST treatments approved by the three regulatory authorities of Japan’s Ministry of Health, Labour and Welfare, the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA) have as their main mechanism of action the inhibition of receptor tyrosine kinases KIT and PDGFRA. There is an unmet medical need for a therapeutic agent to treat GIST that remains after treatment with the drugs currently approved.
About HSP90 (Heat Shock Protein 90)
Cells are constantly exposed to various stresses within the body. Cancer cells in particular are exposed to a lot of stress in the form of hypoxia, malnutrition, elimination by the immune system, and genetic instability. Expression of HSP90 increases in response to stress, protecting cells from stress and promoting cell survival by maintaining the structural and functional integrity of proteins.
HSP90 is overexpressed and exists in a highly active state in cancer cells and tumor tissue, where it is known to be especially important in the survival and maintenance of cancer. Furthermore, it has been reported that the expression of HSP90 in GIST, bladder cancer, acute myelocytic leukemia, breast cancer, non-small cell lung cancer, colorectal cancer, and melanoma correlates with cancer progression and/or a patient’s prognosis
HSP90 is overexpressed and exists in a highly active state in cancer cells and tumor tissue, where it is known to be especially important in the survival and maintenance of cancer. Furthermore, it has been reported that the expression of HSP90 in GIST, bladder cancer, acute myelocytic leukemia, breast cancer, non-small cell lung cancer, colorectal cancer, and melanoma correlates with cancer progression and/or a patient’s prognosis
Similar threads
